SAN DIEGO--(BUSINESS WIRE)--Nov. 4, 2005--Cytori Therapeutics, Inc. (Frankfurt:XMP) announced today the formation of a regenerative medicine collaboration with Olympus Corporation to develop state-of-the-art systems for stem and regenerative cell therapies.

As part of the terms and agreements, the two companies will form a 50:50 Joint Venture, Olympus-Cytori, Inc., to develop and manufacture future generation devices based on Cytori's Celution(TM) System. These devices will process and purify adult stem and regenerative cells residing in adipose tissue, also known as fat. Cytori announced that it independently completed development of the first generation Celution(TM) System in August 2005 and has since submitted CE Mark applications seeking approval for the system in Europe.

"Olympus Corporation, through its leading medical life science business, recognizes the potential of regenerative medicine and the enormous role that adipose stem and regenerative cells could soon play in healthcare," said Yasunobu Toyoshima, General Manager, Head of Medical New Business Project of Olympus. "Cytori's technology represents a novel approach to regenerative medicine, as it enables real-time delivery of autologous stem and regenerative cells. Based on Cytori's progress in the development of therapeutic applications of these cells, we look forward to collaborating on next generation designs of these state-of-the-art devices."

"This alliance creates unique synergies between two companies that share the same vision for regenerative medicine," said Christopher J. Calhoun, Chief Executive Officer for Cytori. "Olympus, as a worldwide leader in the development of innovative medical products, will contribute its expertise in engineering, manufacturing and servicing of sophisticated devices. Strategically, this alignment enables the creation of a premier brand of devices for regenerative medicine to be sold by Cytori. In parallel, Cytori will increase its focus on the development of therapeutic applications for adipose stem and regenerative cells for multiple large markets."

Adipose tissue is an abundant source of stem cells and other regenerative cells that can contribute to the repair and healing of damaged tissue. As a result, this source is uniquely suited for real-time cell therapy utilizing a patient's own cells. It was first reported in April 2001 that stem cells reside in adipose tissue by a team from The University of California, Los Angeles (UCLA), led by Marc H. Hedrick, M.D., now the President of Cytori Therapeutics. In August 2004, the University of California was issued the first composition of matter patent related to adipose stem cells, to which Cytori is the exclusive licensee.

Cytori Therapeutics will host a conference call today at 10:30 a.m. Eastern Standard Time (EST) or 4:30 p.m. Central European Time (CET) to discuss the details of the transaction. The conference call will be webcast live and may be accessed under "Events & Webcasts" in the Investor Relations section of the Company's website at http://www.cytoritx.com . The archived version of the webcast will be available 60 minutes after the call on the company's website and accessible for 90 days. A telephone replay will be available for one week. To access the replay, please call +1 (303) 590-3000 (PIN: 11044174#) or +49 (0) 69 58 99 90 568 (PIN: 133588#).

Cytori Therapeutics, Inc., (Frankfurt:XMP) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution(TM) System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

Olympus launched its business in 1919 and today enjoys a reputation for excellence in digital cameras as well as endoscopes, microscopes, and other medical equipment developed under the concept of opto-digital technology, which is a fusion of traditional optical and advanced digital technologies. In recent years, Olympus has been channeling its energies into developing business operations for human genome analysis systems and regenerative medicine to develop operations in the medical life science business.

This is cache, read story here